Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03082144 : Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Inclusion Criteria:

1. Patients who have been definitely diagnosed as leptomeningeal metastasis according to
cerebrospinal fluid cytology or neuroimaging, or patients who got the clinical
diagnosis by combining with the history of cancer, clinical manifestation,
cerebrospinal fluid examination, neuroimaging etc;

2. Patients who have been diagnosed as malignant solid tumor with definite pathologic
type, excluding hematological malignancies (e.g., leukemia and lymphoma) or primary
brain tumors;

3. No severe abnormal liver and kidney function; WBC?2500/mm3, Plt?60000/mm3;

4. No other severe chronic diseases;

5. No history of severe nervous system disease;

6. No severe dyscrasia;

7. Signed informed consent form.

Exclusion Criteria:

1. Patients with leptomeningeal metastasis from unknown primary tumor;

2. Patients who had received radiotherapy to the brain in the past 6 months;

3. Patients who had accepted systemic chemotherapy within one month before the
treatment, or molecular targeted therapy less than 3 months;

4. Patients with poor compliance, or for other reasons, the researchers considered
unsuitable to participate in this clinical study.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557